BioSpace News Archive

Cogent Biosciences, Inc. today announced the details of its investor webcast being held Monday, June 5, 2023 at 8:00 a.m. ET (7:00 a.m. CT) to discuss lead-in data from its ongoing Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib in patients with Gastrointestinal Stromal Tumors (GIST).

Avalyn Pharma Inc. today presented safety and tolerability data from the ongoing AP01-005 open-label extension (OLE) trial of AP01 (inhaled pirfenidone) , an experimental inhaled drug candidate in development for the treatment of pulmonary fibrosis.

Fresenius Kabi announced it has been awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. Effective May 1, 2023, the new agreement allows Premier members, at their discretion, to benefit from special pricing and terms pre-negotiated by Premier for the Ivenix Infusion System from Fresenius Kabi.

Twist Bioscience Corporation today announced the appointment of Robert Werner as chief accounting officer.

Pathos AI, Inc. (www.pathos.com) announced today that it has entered into a worldwide license agreement to develop FT-7051, a small molecule CBP/p300 inhibitor program from Novo Nordisk as Pathos’ first clinical-stage asset in its pipeline.

Royal Biologics, Inc ., a company specializing in Advanced Cellular & Autologous Technologies for Enhanced Surgical Solutions, today announced the commercial launch of BIO-REIGN the first natural hyper-crosslinked carbohydrate polymer bone graft substitute (BGS).

Aphios announced today that it was awarded an NIH grant to develop a double encapsulated mRNA vaccine for COVID-19 and other diseases.

Checkpoint Therapeutics, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,256,269 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,256,269 shares of common stock and Series B warrants to purchase up to 3,256,269 shares of common stock.

Theralink Technologies , Inc. (OTC: THER) (“Theralink”) and IMAC Holdings, Inc. today announced that they have entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) under which Theralink will merge with a newly-formed wholly-owned subsidiary of IMAC in a stock-for-stock reverse merger transaction (the “Merger”) in which Theralink will survive as a wholly-owned subsidiary of IMAC, a Nasdaq-listed company.

Harbinger Health, a biotechnology company pioneering the detection of early cancer, announced the appointment of May Orfali, M.D., as Chief Medical Officer.